Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-07-13

Clinical Trial Update: Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Genfit completed a Phase 2 trial comparing GFT505 (80 mg) to placebo in adults with Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GFT505

Snippet

Sponsor: Genfit | Conditions: Type II Diabetes Mellitus | Phase 2 | Status: COMPLETED